Omnia SanaSymptom → Plant Sources
Flaxseed (Linum usitatissimum) and Bloating: evidence and sources
inferred from digestive action
For educational purposes only, not medical advice. Always consult a qualified practitioner before using medicinal plants, especially alongside prescribed medication, during pregnancy, or for a serious condition.
Flaxseed is the richest source of the lignan secoisolariciresinol diglucoside (SDG). After ingestion, SDG is converted to secoisolariciresinol, which is further metabolised to the mammalian lignans enterodiol and enterolactone. A growing body of evidence suggests that SDG metabolites may provide health benefits due to their weak oestrogenic or anti-oestrogenic effects, antioxidant activity, ability to induce phase 2 proteins and/or inhibit the activity of certain enzymes, or by mechanisms yet unidentified. Human and animal studies identify the benefits of SDG consumption. SDG metabolites may protect against CVD and the metabolic syndrome by reducing lipid and glucose concentrations, lowering blood pressure, and decreasing oxidative stress and inflammation. Flax lignans may also reduce cancer risk by preventing pre-cancerous cellular changes and by reducing angiogenesis and metastasis. Thus, dietary SDG has the potential to decrease the incidence of several chronic diseases that result in significant morbidity and mortality in industrialised countries. The available literature, though, makes it difficult to clearly identify SDG health effects because of the wide variability in study methods. However, the current evidence suggests that a dose of at least 500 mg SDG/d for approximately 8 weeks is needed to observe positive effects on cardiovascular risk factors in human patients. Flaxseed and its lignan extracts appear to be safe for most adult populations, though animal studies suggest that pregnant women should limit their exposure. The present review discusses the potential health benefits of SDG in humans, with supporting evidence from animal studies, and offers suggestions for future research.
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on VevoVitall ® (benzoic acid) as a feed additive for minor porcine species, when used as zootechnical additive at a maximum level of 5,000 mg/kg complete feed. The safety and efficacy of the additive had been evaluated by the FEEDAP Panel on weaned piglets (at the maximum supplementation level of 5,000 mg/kg complete feed) and pigs for fattening and pigs for reproduction (at the maximum level of 10,000 mg/kg complete feed). Subsequent to EFSA's assessments, the additive has been authorised for use in feed of weaned piglets, pigs for fattening and sows. To the knowledge of the FEEDAP Panel, there was no new information that might modify its previous assessments on VevoVitall ® concerning safety for consumers and the environment; therefore, this opinion focused only on the safety of the target animals and the efficacy of the product. The FEEDAP Panel concluded that VevoVitall ® is safe at the supplementation level of 5,000 mg/kg complete feed for minor porcine species for fattening and for reproduction; the FEEDAP could not conclude on the safety of the additive for weaned minor porcine species. VevoVitall ® does not represent a risk for the consumer and the environment. VevoVitall ® does not pose a risk by inhalation to users and is not skin sensitiser, but is a skin irritant and a severe eye irritant. VevoVitall ® has the potential to decrease the urinary pH in minor porcine species at the dose of 5,000 mg/kg complete feed. A remark on the relevance of the claim has been posted by the Panel.
5 sources supporting Flaxseed for Bloating. Includes scientific publications, books, monographs and traditional-use references.
Mechanistic basis
This use is associated with the plant's digestive aid action. Further evidence for that pharmacology:
The objective of this study was to evaluate the scientific evidence on flaxseed, including expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing. Electronic searches were conducted in 9 databases, 20 additional journals (not indexed in common databases), and bibliographies from 50 selected secondary references. No restrictions were placed on the language or quality of the publications. All literature collected pertained to efficacy in humans, dosing, precautions, adverse effects, use in pregnancy/lactation, interactions, alteration of laboratory assays, and mechanisms of action. Standardized inclusion/exclusion criteria are used for selection. Grades were assigned using an evidence-based grading rationale. A review of the literature on flaxseed yielded 13 categories for which flaxseed had been studied in humans, including constipation/laxative, attention-deficit hyperactivity disorder, hyperlipidemia, atherosclerosis/coronary artery disease, breast cancer, cyclic mastalgia (breast pain), menopausal symptoms, hyperglycemia/diabetes, hypertension, lupus nephritis, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), and prostate cancer. Most of the available evidence investigates the efficacy of alpha-linoleic acid found in flaxseed compared with fish oil, and almost all of the available studies are poor quality. Although flaxseed and flaxseed oil have several promising future uses, the available literature does not support recommendation for any condition at this time.
Introduction and background Linum usitatissimum L., known as common Flax or linseed, from the family Linnaceae, has long been cultivated in different nations due to its applications in medicine and industry. The present study aims to collect nearly all available information about chemical constituents of Flax, as well as pharmacological properties and confirmed clinical usages of it. Methods We searched through databases such as Scopus and PubMed for relevant literature using the keywords: Linum usitatissimum, pharmacology and phytochemical from the beginning to 13 Aug 2017. Nearly 60 relevant papers, relating to a pharmacological and phytochemical constituent of L. usitatissimum were selected. Results and discussion According to our researches, various properties were attributed to L. usitatisimum including antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, antiprotozoal, insecticidal, analgesic, anti-hyperlipidemia, anti-hyperglycemic, anti-tumor, wound healing and Feticidal activities. There were also many reports on disease prevention and healing properties of the flax. Diseases like: GI disorders, cardiovascular, urogenital, respiratory diseases and some neurological syndromes were mentioned to be treated by Flax. The application of Flax in drug formulations was also investigated. Conclusion Despite so much animal studies that have been accomplished, there have not been enough clinical trials done on pharmacological properties of L. usitatissimum. Therefore, this study could be considered as a concise and up to date overview for further facile studies and clinical trials over the valuable plant, L. usitatissimum.